The phrase "I heard it too 2014" refers to a widely misquoted line from ISO 11135-2014, a global standard for ethylene oxide (EO) sterilization validation in medical device manufacturing. The actual text states that validation must account for all process variables, including those detected during routine monitoring-not merely those reported by operators.
ISO 11135-2014 defines requirements for establishing, validating, and monitoring EO sterilization processes used on heat-sensitive medical devices. It specifies how to confirm sterility assurance levels, control gas concentrations, and validate cycle parameters. The standard applies to manufacturers, regulatory bodies, and quality auditors worldwide.
The confusion arose from a misinterpretation of Clause 6.3.2, which requires that all process deviations be evaluated, even if they were not formally reported. A common error is assuming that verbal observations-"I heard it too"-can substitute for documented evidence. The standard demands objective data, not anecdotal input.
The standard uses a risk-based approach to ensure consistent sterility. It mandates that sterilization cycles be validated through multiple runs under controlled conditions. Each cycle must meet defined parameters: temperature, pressure, EO concentration, humidity, and exposure time.
Validation includes biological indicators (BIs) containing spores of *Geobacillus stearothermophilus*. These BIs are placed in critical locations within the chamber. After exposure, they're incubated. If no growth occurs, the cycle is deemed effective. A failure triggers root cause analysis and corrective action.
For example, a manufacturer processing surgical gowns using EO must run at least three consecutive valid cycles. Each cycle records data from sensors measuring EO concentration (typically 600-1200 mg/L), temperature (50-60°C), and humidity (30-70%). Deviations beyond ±5% require investigation.
ISO 11135-2014 outlines three primary validation types:
| Type | Description | Use Case |
|---|---|---|
| Process Validation | Full-cycle testing under worst-case conditions to confirm sterility. | Initial launch of a new product line. |
| Revalidation | Repeat testing after changes to equipment, materials, or packaging. | Switching from polyethylene to polypropylene packaging. |
| Continual Monitoring | Ongoing verification via daily checks and periodic audits. | Tracking EO residuals in finished products. |
Each type follows the same core structure: define the worst-case scenario, run the cycle, collect data, analyze results, and document findings. All data must be traceable to a unique batch ID and timestamp.
One persistent myth is that "I heard it too" implies acceptance of informal feedback. This is incorrect. The standard explicitly requires formal documentation of all process anomalies. Verbal reports-even if confirmed later-are insufficient for compliance.
A real-world example occurred in 2016 at a U.S.-based device manufacturer. An operator noted a slight drop in chamber pressure during a cycle. He reported it verbally to his supervisor. The cycle completed successfully. No BI failed. However, during a subsequent FDA audit, the lack of written record led to a 483 observation. The company had to revalidate six months of production.
Another frequent mistake is assuming that EO residue testing alone confirms sterility. The standard requires both sterility confirmation (via BIs) and residual testing. Residuals must fall below 10 μg/g for most implantable devices, per ISO 10993-7.
Failure to follow ISO 11135-2014 leads to product recalls, regulatory fines, and patient harm. In 2018, a European hospital reported infections linked to improperly sterilized endoscopes. Investigation traced the issue to a facility that skipped revalidation after changing sterilizer filters. The filter change altered EO diffusion patterns. No biological indicator failed-but the device was contaminated.
I once observed a validation team skip recording ambient temperature during a cycle because the reading was "within normal range." The system logged 23°C, but the actual temperature was 28°C due to a faulty sensor. The deviation went unnoticed until a customer reported a burn injury. The incident led to a Class I recall and a $1.2 million fine.
Regulatory bodies like the FDA and EU MDR enforce ISO 11135-2014 through inspections. Non-compliance results in delayed market access, import bans, and loss of certification. The standard is referenced in 14 CFR Part 820.250 and Annex II of Regulation (EU) 2017/745.
"I heard it too 2014" is not a standard clause. It originated as a meme in industry forums after a misreading of Clause 6.3.2. The original text says: "All process deviations shall be recorded and assessed for impact on sterility."
Some teams mistakenly interpret this as allowing informal reporting. The standard requires written logs, electronic records, and audit trails. Any deviation-whether observed by a technician, detected by a sensor, or reported by a customer-must be entered into the quality management system (QMS).
For example, if a sensor detects EO concentration dropping below 600 mg/L, the system must flag the event. The operator cannot rely on "hearing" the alarm. The system must log the time, value, and response action. Failure to do so violates ISO 11135-2014 and may result in a non-conformance report (NCR).
Implement a digital QMS with automated alerts for out-of-spec events. Use calibrated sensors with redundant readings. Train staff to document all observations-even minor ones-in real time.
Run annual revalidations, even if no changes occur. Maintain a master file with all validation protocols, results, and approvals. Retain records for at least ten years past the product's expiry date.
When modifying a sterilization process, perform a risk assessment using FMEA (Failure Mode and Effects Analysis). Document the rationale for any deviation from standard parameters. Submit the plan to a qualified reviewer before implementation.
Understanding "i heard it too 2014" correctly prevents costly errors. The phrase is not a rule-it's a warning against relying on memory, assumptions, or informal communication in sterile processing. True compliance demands precision, documentation, and accountability.